Cargando…
Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E
We report the case of a man with an advanced nonkeratinizing squamous cell thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. This aberration is rare and has never been described previously in patients with thymic cancers. It has been found in a small number of cases of gastrointestin...
Autores principales: | Catania, Chiara, Conforti, Fabio, Spitaleri, Gianluca, Barberis, Massimo, Preda, Lorenzo, Noberasco, Cristina, Lazzari, Chiara, Toffalorio, Francesca, de Marinis, Filippo, Manzotti, Michela, De Pas, Tommaso Martino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020909/ https://www.ncbi.nlm.nih.gov/pubmed/24855380 http://dx.doi.org/10.2147/OTT.S58902 |
Ejemplares similares
-
Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)
por: Spitaleri, Gianluca, et al.
Publicado: (2015) -
Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
por: Passaro, Antonio, et al.
Publicado: (2016) -
Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma
por: De Pas, T, et al.
Publicado: (2008) -
5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer
por: Toffalorio, Francesca, et al.
Publicado: (2018) -
Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review
por: Digiacomo, Nunzio, et al.
Publicado: (2023)